Mp38-02 Patterns of Non-Urothelial Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma (Ucan Collaboration)

You have accessJournal of UrologyBladder Cancer: Upper Tract Transitional Cell Carcinoma II (MP38)1 May 2024MP38-02 PATTERNS OF NON-UROTHELIAL RECURRENCE AFTER NEPHROURETERECTOMY FOR UPPER TRACT UROTHELIAL CARCINOMA (UCAN COLLABORATION) Andrew B. Katims, Amy L. Tin, Patrick Hensley, Roger Li, Vitaly Margulis, Surena Matin, Maximilian Pallauf, Jonathan Pham, Jay D. Raman, Nirmish Singla, Philippe E. Spiess, and Jonathan Coleman Andrew B. KatimsAndrew B. Katims , Amy L. TinAmy L. Tin , Patrick HensleyPatrick Hensley , Roger LiRoger Li , Vitaly MargulisVitaly Margulis , Surena MatinSurena Matin , Maximilian PallaufMaximilian Pallauf , Jonathan PhamJonathan Pham , Jay D. RamanJay D. Raman , Nirmish SinglaNirmish Singla , Philippe E. SpiessPhilippe E. Spiess , and Jonathan ColemanJonathan Coleman View All Author Informationhttps://doi.org/10.1097/01.JU.0001008700.92603.b1.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: After radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), 25% of patients will experience distant metastasis in the first 5 years. Non-urothelial recurrence is associated with worse prognosis and survival, with ∼80% of patients dying from disease within 2 years. We evaluated the timing and pattern of recurrences after RNU as well as the association of cancer specific survival (CSS) and location of recurrence. METHODS: We identified patients with UTUC who underwent RNU between 01/2000-02/2021 from seven institutions. We categorized recurrences based on site and used competing risk regression models with each site as the main outcome (vs. all other recurrence sites as the competing risk). Cox proportional hazards regression model with time from recurrence to death from disease was created to evaluate the association between CSS and location of recurrence, adjusted for time from surgery to recurrence. A separate model including an indicator for multiple sites was used to assess its association with CSS, after adjusting only for the sites found to be significant in the previous model. RESULTS: 2177 patients were included, among whom 454 developed non-urothelial recurrence (median follow up among survivors was 34 (IQR 11, 70) months). The cumulative incidence of recurrence per site is seen in Figure 1. Risk of CSS based on location of recurrence (p<0.001) is seen in Table 1. Better rates of CSS were seen in lung and lymph node (LN) metastasis (HR 0.60, 95% CI 0.37, 0.97, p=0.038; HR 0.65, 95% CI 0.41, 1.02, p=0.063, respectively). Recurrence to multiple concurrent non-urothelial sites was associated with worse rates of CSS (HR 1.68, 95% CI 1.30, 2.17, p<0.001). CONCLUSIONS: Recurrences mostly occurred within the first 2 years located in the LN or lung which portended the most favorable CSS. These data can be used to inform surveillance strategies after RNU. Download PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e640 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Andrew B. Katims More articles by this author Amy L. Tin More articles by this author Patrick Hensley More articles by this author Roger Li More articles by this author Vitaly Margulis More articles by this author Surena Matin More articles by this author Maximilian Pallauf More articles by this author Jonathan Pham More articles by this author Jay D. Raman More articles by this author Nirmish Singla More articles by this author Philippe E. Spiess More articles by this author Jonathan Coleman More articles by this author Expand All Advertisement PDF downloadLoading ...